TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 16053953
Drug: Eplerenone 25
Normalized name: eplerenone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplerenone 25 mg/day
Study: 12493339
Drug: Cilomilast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast (10 mg twice daily) plus nebulised salbutamol (2.5 mg)
Study: 12493339
Drug: Cilomilast (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilomilast (10 mg twice daily) plus nebulised placebo
Study: 12493339
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus nebulised salbutamol (2.5 mg)
Study: 7659146
Drug: Trimethoprim 80
Normalized name: trimethoprim 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 80 mg-sulfamethoxazole 400 mg (TMP-SMX) orally twice per day for one month
Study: 7659146
Drug: Trimethoprim 80
Normalized name: trimethoprim 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimethoprim 80 mg-sulfamethoxazole 400 mg (TMP-SMX) orally twice per day for one month + frequent ejaculation (at least once every three days) for one month
Study: 1270775
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene therapy three times weekly for 5 weeks
Study: 31307501
Drug: LED-RL (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED-RL (all doses)
Study: 23485539
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose of daclizumab (1 mg/kg) before and 14 days after transplantation
Study: 23485539
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment protocol only
Study: 21644317
Drug: Santong tuina
Normalized name: santonin
DrugBank: Santonin (DB19377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Santong tuina therapy
Study: 21644317
Drug: Conventional tuina
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tuina therapy
Study: 19250106
Drug: Warfarin (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (target INR 2.0-3.5)
Study: 17026489
Drug: RSG/MET fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/MET fixed-dose combination therapy (initial dose 2 mg/500 mg, uptitrated to 8 mg/2000 mg)
Study: 17026489
Drug: RSG/MET fixed-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG/MET fixed-dose combination therapy
Study: 17026489
Drug: MET monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MET monotherapy (initial dose 500 mg, uptitrated to 2000 mg)
Study: 17026489
Drug: RSG monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSG monotherapy (initial dose 4 mg, uptitrated to 8 mg)
Study: 9073134
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal nitroglycerin (5 mg/day)
Study: 9073134
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal nitroglycerin plus spironolactone (100 mg/day)
Study: 9073134
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal nitroglycerin
Study: 9073134
Drug: Low-dose transdermal
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose transdermal nitroglycerin plus spironolactone
Study: 105386
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with a mixture of carbohydrate and essential L-amino acids
Study: 31701308
Drug: Dexmedetomidine (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.3 µg/kg)
Study: 22712503
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) with medical treatment as usual, 8 sessions
Study: 22712503
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received only medical treatment as usual
Study: 18301120
Drug: Atypical antipsychotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atypical antipsychotics (e.g., olanzapine, risperidone, quetiapine)
Study: 18301120
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors and serotonin‐noradrenaline reuptake inhibitors
Study: 12592551
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of methylprednisolone intravenously at the end of the operation and 12 and 24 hours later (group II)
Study: 10560385
Drug: HAI chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI chemotherapy (12 g of 5‐FU administered in 6 weeks)
Study: 10560385
Drug: HAI chemotherapy
Normalized name: cromolyn sodium Ophthalmic Solution [Hay-Crom Hay Fever]
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAI chemotherapy (1,000-1,500 mg/w of 5‐FU)
Study: 7472904
Drug: fermented whey-adapted
Normalized name: whey protein hydrolysate
Approvals — FDA: no, EMA: no, PMDA: no
Description: fermented whey-adapted infant formula containing viable bifidobacteria (10^6/g of powder)
Study: 2337034
Drug: Aspirin 60
Normalized name: aspirin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 60 mg/kg/day for 7 days starting on the third postoperative day (group 1, 32 patients)
Study: 2337034
Drug: No aspirin
Normalized name: XS No Aspirin PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: No aspirin (group 2, 42 patients)
Study: 2337034
Drug: Aspirin 60
Normalized name: aspirin 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 60 mg/kg/day for 7 days
Study: 29802215
Drug: Aspirin prophylaxis
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin prophylaxis
Study: 28952201
Drug: Aprepitant plus
Normalized name: Aprepitant
DrugBank: Aprepitant (DB00673)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aprepitant plus palonosetron (administered with dexamethasone)
Study: 25546165
Drug: Triflusal (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (900 mg) under fasting condition
Study: 25546165
Drug: Triflusal (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (900 mg) under fed condition (after a high-fat meal)
Study: 21161171
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (machine not turned on)
Study: 15075653
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin (BoTx) injection, 8 to 100 units injected twice, a month apart at the esophagogastric junction.
Study: 3299178
Drug: Alprazolam 0.25
Normalized name: alprazolam 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 0.25 mg administered three times daily from cycle day 20 until the second day of menstruation, tapered by one tablet per day thereafter.
Study: 3299178
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered three times daily from cycle day 20 until the second day of menstruation, tapered by one tablet per day thereafter.
Study: 27169838
Drug: Orange maizemeal
Normalized name: Orange
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange maizemeal (200 g, 6 days/week for 6 months)
Study: 27169838
Drug: White maizemeal
Normalized name: White Petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: White maizemeal (200 g, 6 days/week for 6 months)
Study: 25035292
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronic acid (4 mg intravenous every 3-4 weeks for six doses, then every 3 months for eight doses, followed by every 6 months for five doses, for a total of 5 years)
Study: 10689845
Drug: Nicorandil infusion
Normalized name: nicorandil
DrugBank: Nicorandil (DB09220)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicorandil infusion
Study: 1482152
Drug: TMP-SMX (160:800
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP-SMX (160:800 mg twice daily for six doses)
Study: 1482152
Drug: Single large
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single large dose of TMP-SMX (320:1,600 mg)
Study: 1482152
Drug: Large loading
Normalized name: Bos taurus large intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Large loading dose (320:1,600 mg) followed by standard doses (160:800 mg twice daily for five doses)
Study: 1482152
Drug: Loperamide (4-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Loperamide (4-mg loading dose; 2 mg after each loose stool, not to exceed 16 mg/day for 3 days)
Study: 6541200
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc as an adjunct to dapsone
Study: 30556410
Drug: Endoventricular patch
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoventricular patch
Study: 3885984
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg domperidone
Study: 19555938
Drug: Water infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water infusion in lieu of air insufflation
Study: 17230049
Drug: Volition group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Volition group therapy in addition to standard cognitive behavioral therapy (VG)
Study: 17230049
Drug: Standard cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard cognitive behavioral therapy (SG)
Study: 15100505
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of 99mTc-tetrofosmin
Study: 15100505
Drug: Intravenous injection
Normalized name: Meta Trace FDG, intravenous injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection of 99mTc-tetrofosmin
Study: 11581449
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 1 to 2 ppm (low-dose group)
Study: 11581449
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) at 10 to 20 ppm (high-dose group)
Study: 11581449
Drug: Higher doses
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher doses of iNO after initial treatment
Study: 10923477
Drug: H2 strain
Approvals — FDA: no, EMA: no, PMDA: no
Description: H2 strain vaccine (10^7.0 TCID50)
Study: 10923477
Drug: LA-1 strain
Normalized name: Haemagglutinin-strain B
DrugBank: Haemagglutinin-strain B (DB15482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LA-1 strain vaccine (10^6.75 TCID50)
Study: 10923477
Drug: Combined efficacy
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined efficacy of H2 and LA-1 vaccines
Study: 29791895
Drug: Postprandial ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postprandial ingestion of esomeprazole 40 mg
Study: 29791895
Drug: Preprandial ingestion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprandial ingestion of esomeprazole 40 mg
Study: 25636696
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg once daily for 5 days + HCTZ 25 mg once daily for 4 days
Study: 25636696
Drug: Empagliflozin 25
Normalized name: empagliflozin 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 25 mg once daily for 5 days + TOR 5 mg once daily for 4 days
Study: 25636696
Drug: HCTZ 25
Normalized name: HCTZ 25 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ 25 mg once daily
Study: 25636696
Drug: TOR 5
Normalized name: T-Connector 5"
Approvals — FDA: no, EMA: no, PMDA: no
Description: TOR 5 mg once daily
Study: 23916935
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) niacin 1,500 to 2,000 mg
Study: 23916935
Drug: Minimal immediate-release
Normalized name: Centipeda minima whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal immediate-release niacin (≤ 150 mg) as placebo
Study: 18945506
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus LC705 and Propionibacterium freudenreichii ssp. shermanii JS (2x10(10) CFU of each strain daily)
Study: 10506617
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + RT (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 every 21 days for up to four cycles followed by radical radiotherapy)
Study: 10506617
Drug: CT +
Normalized name: Aveeno Protect + Hydrate SPF70 Lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT + PC (mitomycin 6 mg/m2, ifosfamide 3 g/m2, cisplatin 50 mg/m2 plus palliative care)
Study: 10506617
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (RT or PC)
Study: 26164621
Drug: Group family‐based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group family‐based cognitive behavioural therapy (CBT)
Study: 19343318
Drug: Caroverine (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caroverine (80 mg)
Study: 11057406
Drug: Intraderma injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraderma injection of Tc‐99m nanocolloid
Study: 11057406
Drug: Peritumoural injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritumoural injection of Tc‐99m nanocolloid
Study: 11057406
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of both injection methods
Study: 8790025
Drug: Hirudin (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirudin (0.1 mg/kg bolus followed by infusion of 0.1 mg/kg per hour)
Study: 8790025
Drug: Heparin (5000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin (5000 U bolus followed by infusion of 1000 U/h)
Study: 1535215
Drug: Topical erythromycin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical erythromycin
Study: 19923168
Drug: Ticagrelor (180‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor (180‐mg load, 90‐mg BID maintenance dose)
Study: 19923168
Drug: Clopidogrel (600‐mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel (600‐mg load, 75‐mg/d maintenance dose)
Study: 17876889
Drug: Low-dose intermittent
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intermittent interferon (IFN) therapy (3 MIU of natural IFN‐alpha intramuscularly 3 times weekly for at least 48 weeks)
Study: 17876889
Drug: Low-dose intermittent
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intermittent interferon (IFN) therapy
Study: 16009829
Drug: Latanoprost therapy
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Latanoprost therapy alone
Study: 16009829
Drug: Latanoprost-timolol-fixed combination
Normalized name: latanoprost / timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Latanoprost-timolol-fixed combination therapy
Study: 12774194
Drug: Calcitriol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitriol (0.5 micro g p.o. b.i.d. for 14 days)
Study: 8966497
Drug: Premarin 0.625
Normalized name: Premarin 0.625mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premarin 0.625 mg
Study: 8966497
Drug: Menorest 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Menorest 50 mikrog/day and Premarin 0.625 mg
Study: 1563807
Drug: Albendazole 10
Normalized name: albendazole 100 % MISCELL POWDER (GRAM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole 10 mg/kg/day for four courses of 30 days with 15‐day drug‐free intervals
Study: 1563807
Drug: Mebendazole 50‐70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mebendazole 50‐70 mg/kg/day continuously for between 6 and 24 months
Study: 6386490
Drug: UK‐38,485 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: UK‐38,485 50 mg
Study: 16905139
Drug: High-dose lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose lovastatin
Study: 16905139
Drug: Low-dose lovastatin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose lovastatin
Study: 16905139
Drug: Overall treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall treatment effects (lovastatin and warfarin vs placebo)
Study: 17315548
Drug: Transdermal therapeutic
Normalized name: Moisturel Therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal therapeutic fentanyl (TTS‐F) patches releasing 25 microg fentanyl per hour
Study: 17315548
Drug: Codeine/paracetamol (120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Codeine/paracetamol (120 mg per day)
Study: 12354129
Drug: Individualized recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized recombinant GH substitution (0.17 mg GH/day, titrated every 6-8 weeks)
Study: 12354129
Drug: Individualized recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized recombinant GH substitution (0.17 mg GH/day, titrated to T(max) and then reduced to T(end))
Study: 2299950
Drug: Blunt dissection
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Blunt dissection tonsillectomy using suture ligatures for hemostasis, without postoperative antibiotics
Study: 6109150
Drug: Dipyridamole (DPY),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (DPY), 100 mg a day and Aspirin (ASA), 1200 mg a day
Study: 6109150
Drug: Dipyridamole (DPY)
Normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dipyridamole (DPY) and Aspirin (ASA)
Study: 23475825
Drug: Immediate-release methylphenidate
Normalized name: methylphenidate Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release methylphenidate (IR-methylphenidate)
Study: 23036139
Drug: Naturopathic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naturopathic and nutritional supplements (NNS)
Study: 23036139
Drug: No Naturopathic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Naturopathic and nutritional supplements (NNS)
Study: 19173973
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of lamivudine and traditional Chinese medicine
Study: 14594786
Drug: Spread A
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spread A (25 g/d containing 43 mg alpha‐TE and 0.45 mg carotenoids)
Study: 14594786
Drug: Spread B
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread B (25 g/d containing 111 mg alpha‐TE and 1.24 mg carotenoids)
Study: 14594786
Drug: Spread C
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spread C (25 g/d containing 1.3 mg RRR‐alpha‐tocopherol without carotenoids)
Study: 8853832
Drug: Granisetron 2
Normalized name: granisetron 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Granisetron 2 mg oral dose
Study: 1633756
Drug: Sham transdermal
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham transdermal stimulation
Study: 6392119
Drug: xipamid (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: xipamid (40 mg)
Study: 6392119
Drug: hydrochlorothiazide (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (50 mg)
Study: 6392119
Drug: xipamid (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: xipamid (80 mg)
Study: 6392119
Drug: hydrochlorothiazide (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: hydrochlorothiazide (100 mg)
Study: 29764262
Drug: IgPro20 (20%
Approvals — FDA: no, EMA: no, PMDA: no
Description: IgPro20 (20% IgG stabilized with L‐Proline)
Study: 29764262
Drug: Subcutaneous method
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous method
Study: 26901268
Drug: Comparison treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison treatment with a print manual plus telephone follow‐ups
Study: 15480323
Drug: Sublingual immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual immunotherapy (SLIT) for 2 years
Study: 18508833
Drug: Consecutive C-reactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consecutive C-reactive protein (CRP) measurements on admission, day 3, and day 7 during follow-up of antibiotic treatment.
Study: 15889132
Drug: Inhaled nitric
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nitric oxide (iNO) therapy for 1 to 72 hours
Study: 9202910
Drug: Tenoxicam 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam 40 mg intravenous (i.v.)
Study: 7960608
Drug: E (epirubicin)
Approvals — FDA: no, EMA: no, PMDA: no
Description: E (epirubicin) alone (90 mg/m2 day 1)
Study: 7960608
Drug: 5‐FU (5-Fluorouracil)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (5-Fluorouracil) alone (500 mg/m2 days 1‐5)
Study: 7960608
Drug: 5‐FU (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU (400 mg/m2 days 1‐5) plus E (epirubicin) (90 mg/m2 day 1)
Study: 30334066
Drug: Weekly cone
Normalized name: Pinus strobus cone extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly cone beam CTs (CBCT)
Study: 23884915
Drug: Oral T4
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral T4 (2 μg·kg⁻¹)
Study: 23884915
Drug: Intravenous T4
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous T4 (2 μg·kg⁻¹)
Study: 23884915
Drug: Oral T4
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral T4
Study: 23884915
Drug: Intravenous T4
Normalized name: T4
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous T4
Study: 22043670
Drug: Western medication
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medication group (Fluoxetine Hydrochloride capsule, 20 mg, once a day)
Study: 15304961
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of potassium iodide (38 mg of iodide)
Study: 15304961
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of potassium iodide (76 mg of iodide)
Study: 9299652
Drug: Ipratropium bromide
Normalized name: Ipratropium Bromide
DrugBank: Ipratropium (DB00332)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ipratropium bromide (400 micrograms, 4 times daily for 3 days)